AL
Alpa Laboratories Ltd (ALPA)
₹49.92
Mkt cap
₹109 Cr
P/E ratio
52.00
P/B
0.56
Div yield
0.00%
ROE
8.38%
ROCE
9.40%
EPS (TTM)
₹0.96
Book value
₹88
52W range
46–93
Sector
Healthcare
Price history
Previous close
Incorporated in 1988, Alpa Laboratories Ltd manufactures and sells Drugs and Chemicals [1]
NSE ALPABSE 532878
Health check
Cautious
ValuationExpensive
ProfitabilityWeak
GrowthModerate
TechnicalsBearish
52-week range
−46.03% from high₹50
₹46+8.29% from low₹93
Current
₹49.92
Prev close
₹50.64
Day
−1.42%
Price performance
1D
−2.15%
1W
−11.49%
1M
−3.71%
3M
−20.21%
6M
−28.77%
1Y
−42.33%
YTD
−36.03%
Financials
Revenue, profit & margin
P/E ratio
52.0×
ALPA is 56% above the sector median of 33.4×
ALPA52.0×
Sector median33.4×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 32.39 | 27.31 | 23.61 | 21.44 | 24.94 | 26.15 | 39.92 | 19.11 | 26.26 | 29.05 | 31.40 | 23.93 | 30.98 | |
| YoY Sales growth | +139.22% | +0.00% | -19.03% | -15.69% | -23.00% | -4.25% | +69.08% | -10.87% | +5.29% | +11.09% | -21.34% | +25.22% | +17.97% | |
| Expenses | 29.04 | 24.88 | 20.10 | 20.91 | 21.62 | 25.41 | 39.72 | 18.68 | 28.51 | 27.54 | 27.80 | 27.89 | 33.21 | |
| Operating Profit | 3.35 | 2.43 | 3.51 | 0.53 | 3.32 | 0.74 | 0.20 | 0.43 | -2.25 | 1.51 | 3.60 | -3.96 | -2.23 | |
| OPM % | 10.34% | 8.90% | 14.87% | 2.47% | 13.31% | 2.83% | 0.50% | 2.25% | -8.57% | 5.20% | 11.46% | -16.55% | -7.20% | |
| Other Income | 2.95 | 3.55 | 3.98 | 5.16 | 6.91 | 8.80 | 2.48 | 11.94 | 3.06 | 0.91 | -0.16 | 5.77 | 1.24 | |
| Interest | 0.02 | 0.02 | 0.29 | 0.05 | 0.05 | 0.09 | 0.02 | 0.05 | 0.03 | 0.03 | 0.15 | 0.11 | 0.10 | |
| Depreciation | 0.49 | 0.66 | 0.52 | 0.54 | 0.53 | 0.55 | 0.58 | 0.55 | 0.67 | 0.65 | 0.22 | 0.72 | 0.76 | |
| Profit before tax | 5.79 | 5.30 | 6.68 | 5.10 | 9.65 | 8.90 | 2.08 | 11.77 | 0.11 | 1.74 | 3.07 | 0.98 | -1.85 | |
| Tax % | 0.00% | 14.91% | 46.71% | 0.00% | 20.31% | 0.00% | 201.92% | 0.00% | 0.00% | 9.20% | 55.05% | 0.00% | 0.00% | |
| Net Profit | 5.79 | 4.51 | 3.55 | 5.10 | 7.69 | 8.90 | -2.12 | 11.77 | 0.11 | 1.59 | 1.38 | 0.98 | -1.85 | |
| EPS in Rs | 2.75 | 2.14 | 1.69 | 2.42 | 3.65 | 4.23 | -1.01 | 5.59 | 0.05 | 0.76 | 0.66 | 0.47 | -0.88 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −2.40% · closed higher next day 0 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 13 Aug '26◦ |
| Earnings day | −2.40% |
| +1 day | −3.23% |
| +5 days | −4.71% |
| +15 days | −4.77% |
| +30 days | −10.08% |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Results analysis
Shareholding
as of Sep 202657.19%Promoter
Promoters57.19%
FIIs0.35%
DIIs0.07%
Public42.39%
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,870.00 | 36.46 | 4,48,676 | 0.86% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,150.00 | 86.62 | 2,95,997 | 0.27% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,668.80 | 81.80 | 1,77,586 | 0.81% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,338.00 | 94.28 | 1,26,325 | 0.09% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,204.20 | 26.51 | 1,20,119 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,388.00 | 41.41 | 1,15,936 | 0.58% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,388.00 | 36.11 | 1,12,135 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Alpa Laboratorie | ₹51.95 | 52.05 | 109 | 0.00% | −2 | −1,781.82% | 31 | +17.97% | 9.40% |
| Median: 160 Co. | ₹445.73 | 33.35 | 2,016 | 0.08% | 13 | +33.73% | 179 | +21.23% | 14.94% |
Filings
Annual reports15
Credit ratings6
Announcements5
Board Meeting Outcome for Results For The Quarter And Half Year Ended September 30,2026. 14 Nov - Board approved unaudited standalone and consolidated results for quarter and half year ended 30 September 2026.Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results Of The Company For The Quarter And Half Year Ended On 30Th September, 2026 Along With Limited Review Report Thereon. 4 Nov - Board meets November 14, 2026 to approve Q2 and half-year unaudited results; trading window closed till 48 hours post घोषणा.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 14 Oct - Alpa Laboratories Limited hereby submit to the Exchange the Certificate under Regulation 74(5) of SEBI (Depositories and Prticipants) Regulations, 2018.Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 12 OctShareholder Meeting / Postal Ballot-Outcome of AGM 30 Sep - 38th AGM held on 30 Sep 2026; shareholders approved financials, MD reappointment, independent director and Rs160 crore loan authority.






